Our systematic review on the prevalence of HER2 mutations and amplification in NSCLC was analysed from a total of 76 articles; most articles described studies originated from East Asia, North America or Europe, with variations in the testing method used. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.